Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
Background/AimsErlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors for chemotherapeutic response in Korean pancreatic cancer patients....
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
Gastroenterology Council for Gut and Liver
2013-09-01
|
| Series: | Gut and Liver |
| Subjects: | |
| Online Access: | http://gutnliver.org/journal/view.html?doi=10.5009/gnl.2013.7.5.611 |